Nine versus 52 weeks of adjuvant trastuzumab in early breast cancer: An observational study of the Turkish Oncology Group.


Icli F., Altundag K., Coskun U., Paydas S., BAŞARAN G., Saip P., ...More

JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (SCI-Expanded) identifier